Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pharma Q3 Results Preview: Merck Vs. Bristol In IO Showdown

Oct 22 2018

• By Emily Hayes

Female athletes running towards finish line on track field

Related Content

Stellar Survival Data For AZ's Lynparza Hailed At ESMO

Oct 22 2018

Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory

Oct 18 2018

Bristol’s Checkmate-331 Failure Not Likely To Endanger SCLC Labeling For Opdivo

Oct 12 2018

Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner

Apr 17 2018

Tecentriq's Small-Cell Lung Cancer Success Takes Edge Off Roche's IO Position

Sep 26 2018

Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear

Sep 12 2018

Merck To Build Case For Doravirine-Based HIV Products On Efficacy, Safety Differences

Aug 31 2018

Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO

Jun 06 2018

TMB Biomarker Is A Winding Path Rather Than Straight Road

Jun 14 2018

First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo

Jul 30 2018

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Merck KGaA

Pfizer Inc.

AstraZeneca PLC

Additional Topics

Sales & Earnings Business Strategies Commercial Cancer BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window